ScreenerHero
B8FKBiofrontera AGPartial data
XETRA · DE · Healthcare · Drug Manufacturers - Specialty & Generic · biofrontera.com
2.540EUR-1.17%Mkt Cap: 16.78M $P/E: —

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap16.78M $
Enterprise Value12.04M $
Revenue (TTM)14.81M $
Gross Profit11.86M $
Net Income (TTM)-4.31M $
Revenue/Share2.443 USD
Last Price2.540 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees69
CountryDE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINDE000A4BGGM7
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-17.48
EV/Revenue0.81
P/S1.06
P/B0.84
EPS (TTM)-1.09
EPS (Forward)—
52W Range
2.22043% of range2.960
52W High2.960 EUR
52W Low2.220 EUR
Profitability
Gross Margin82.71%
Oper. Margin0.24%
EBITDA Margin-4.65%
Profit Margin-30.06%
ROE-26.60%
ROA-19.21%
Growth
Revenue Growth13.40%
Earnings Growth227.30%
Cash Flow & Leverage
Operating CF-4.78M $
CapEx (TTM)55.43K $
FCF Margin—
FCF Yield—
Net Debt-4.07M $
Net Debt/EBITDA5.91
Balance Sheet
Debt/Equity0.00
Current Ratio2.96
Quick Ratio2.07
Book Value/Sh2.813 EUR
Cash/Share0.9280 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:21
Split DateMay 14, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.6.08M
Float1.40M
Insiders27.00%
Institutions0.00%
Technical
SMA 502.436 (+4.3%)
SMA 2002.526 (+0.5%)
Beta-0.23
S&P 52W Chg19.97%
Avg Vol (30d)1.29K
Avg Vol (10d)919
Technical Indicators
RSI (14)57.1
MACD-0.0052
MACD Signal-0.0257
MACD Hist.+0.0204
BB Upper2.671 EUR
BB Middle2.434 EUR
BB Lower2.198 EUR
BB Width19.45%
ATR (14)0.1109 EUR
Vol Ratio (20d)1.48x